Program
BNT162 Vaccine
Also written as “BNT162b2”, “BNT162b1” and “BNT162b2 Vaccine”.
Its studies are mostly in COVID-19 · Influenza, Human · Pneumococcal Infections, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 202 open or running | phase 4since Oct 14, 2020 | Apr 27, 2020 | Apr 21, 2027phase 3 · NCT07798648 |
| Pfizer | 20 open or running | phase 3since May 10, 2021 | May 10, 2021 | none ahead |
| PharmaJet | 11 open or running | phase 2since Apr 3, 2025 | Apr 3, 2025 | none ahead |
Also a collaborator on its studies: Fosun Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Apr 27, 2020.
- May 5, 2021Phase 2 study in COVID-19BioNTech · NCT04895982 · 124 enrolled · United States, Brazil, Germany and more
- May 10, 2021Pfizer's first study: phase 3 study in Pneumococcal InfectionsNew to PfizerPfizer · NCT04887948 · 570 enrolled · United States
- Jun 9, 2021Phase 3 study in COVID-19BioNTech · NCT04955626 · 16,372 enrolled · United States, Brazil, Germany and more
- Jun 25, 2021Phase 2 study in COVID-19BioNTech · NCT04949490 · 137 enrolled · Germany
- Aug 5, 2021Phase 2 study in COVID-19BioNTech · NCT05004181 · 1,380 enrolled · United States, Germany, South Africa and more
- Mar 25, 2022Phase 3 study in COVID-19BioNTech · NCT05310084 · 1,134 enrolled · Australia, New Zealand
- Aug 10, 2023Phase 3 study in COVID-19BioNTech · NCT05997290 · 1,051 enrolled · United States
- Jan 30, 2024Phase 2 study in Influenza, HumanPfizer · NCT06237049 · 644 enrolled · United States
- Apr 3, 2025PharmaJet's first study: phase 2 study in Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy VolunteersNew to PharmaJetPharmaJet · NCT06919796 · 40 planned · United States
- Jul 7, 2025Phase 3 study in COVID-19BioNTech · NCT07069309 · 774 enrolled · United States
- Oct 28, 2025Phase 3 study in COVID-19BioNTech · NCT07222384 · 344 enrolled · United States, Puerto Rico
- Nov 27, 2025Phase 3 study in COVID-19BioNTech · NCT07300839 · 5,240 enrolled · United States
- Jul 23, 2026Phase 4 study in PneumoniaBioNTech · NCT07730450 · 200 planned · United States
- Aug 28, 2026Phase 3 study in PneumoniaBioNTech · NCT07798648 · 700 planned · United States
Ahead
- Apr 21, 2027Primary completion: phase 3 study in PneumoniaBioNTech · NCT07798648
- Aug 20, 2027Primary completion: phase 4 study in PneumoniaBioNTech · NCT07730450
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07798648Pneumonia · United States | 3 | Recruiting | BioNTech | Apr 21, 2027 | 700 |
| NCT07730450Pneumonia · United States | 4 | Recruiting | BioNTech | Aug 20, 2027 | 200 |
| NCT07300839COVID-19 · United States | 3 | Completed | BioNTech | Sep 22, 2026 | 5,240 |
| NCT07222384COVID-19 · United States, Puerto Rico | 3 | Completed | BioNTech | Jul 24, 2026 | 344 |
| NCT07069309COVID-19 · United States | 3 | Completed | BioNTech | May 1, 2026 | 774 |
| NCT06919796Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers · United States | 2 | Not yet recruiting | PharmaJet | May 1, 2026 | 40 |
| NCT06237049Influenza, Human · United States | 2 | Completed | Pfizer | Sep 13, 2024 | 644 |
| NCT05997290COVID-19 · United States | 3 | Completed | BioNTech | Mar 13, 2025 | 1,051 |
| NCT05310084COVID-19 · Australia, New Zealand | 3 | Completed | BioNTech | Oct 5, 2022 | 1,134 |
| NCT05004181COVID-19 · United States, Germany, South Africa and more | 2 | Completed | BioNTech | Aug 16, 2023 | 1,380 |
| NCT04949490COVID-19 · Germany | 2 | Completed | BioNTech | Apr 14, 2022 | 137 |
| NCT04955626COVID-19 · United States, Brazil, Germany and more | 3 | Completed | BioNTech | May 25, 2023 | 16,372 |
| NCT04887948Pneumococcal Infections · United States | 3 | Completed | Pfizer | Dec 8, 2021 | 570 |
| NCT04895982COVID-19 · United States, Brazil, Germany and more | 2 | Completed | BioNTech | Jul 23, 2023 | 124 |
| NCT04816669COVID-19 · United States | 3 | Completed | BioNTech | Dec 1, 2021 | 629 |
| NCT04816643COVID-19 · United States, Brazil, Finland and more | 3 | Completed | BioNTech | Oct 4, 2023 | 11,837 |
| NCT04754594COVID-19 · United States, Brazil, South Africa and more | 3 | Completed | BioNTech | Jul 15, 2022 | 726 |
| NCT04713553COVID-19 · United States | 3 | Completed | BioNTech | Jul 22, 2021 | 1,574 |
| NCT04649021COVID-19 · China | 2 | Completed | BioNTech | Feb 7, 2021 | 960 |
| NCT04588480COVID-19 · Japan | 4 | Completed | BioNTech | Nov 25, 2021 | 160 |
| NCT04523571COVID-19 · China | 1 | Completed | BioNTech | Sep 30, 2020 | 144 |
| NCT04380701Respiratory Tract Infections · Germany | 2 | Completed | BioNTech | Jun 30, 2021 | 512 |
| NCT04368728COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | BioNTech | Feb 10, 2023 | 46,969 |
How it is read
Names in the registry
- “BNT162b2”, 16 entries
- “BNT162b1”, 3 entries
- “BNT162b2 Vaccine”, 2 entries
- “BNT162b2 (Omi XBB.1.5)”, 2 entries
- “BNT162b2 (2025/2026 formulation)”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 21 studies
- Influenza, Human, 1 study
- Pneumococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.